Androgen Insensitivity Syndrome (AIS) Cell Models for Research

Androgen Insensitivity Syndrome (AIS) is a rare X-linked recessive disorder caused by mutations in the androgen receptor (AR) gene. The exact prevalence is unknown, but it is estimated to affect 1 in 20,000 to 1 in 99,000 individuals with a 46,XY karyotype (WHO, 2023). AIS is categorized into complete (CAIS), partial (PAIS), and mild (MAIS) forms based on the degree of androgen insensitivity. Individuals with CAIS typically have female external genitalia, while those with PAIS may have ambiguous genitalia. The condition is not associated with increased mortality, but it has significant psychological and reproductive health impacts. Early diagnosis and multidisciplinary management are crucial. Research on AIS is vital for understanding androgen signaling, sex differentiation, and developing targeted therapies for related conditions such as prostate cancer.

AIS provides a unique model to study androgen receptor function in various tissues. The AR gene encodes a nuclear receptor that regulates gene expression in response to androgens. Mutations in AR lead to loss of function, affecting male sexual development. AIS is ideal for mechanistic studies because:

• • The AR signaling pathway is well-characterized and involves multiple co-regulators.
• • Public datasets, such as those from ClinVar and UniProt, provide comprehensive mutation data.
• • Open questions remain about the genotype-phenotype correlation and the role of AR in non-classical tissues.
• • Gene-edited cell models with specific AR mutations can help dissect the functional consequences of individual variants.

While AIS itself is not a cancer, AR signaling is implicated in prostate cancer and other malignancies. The major pathways include:

1. Androgen receptor signaling: Androgens bind to AR, which translocates to the nucleus and regulates transcription of target genes.

2. PI3K/AKT pathway: AR can interact with PI3K/AKT to promote cell survival and proliferation.

3. MAPK/ERK pathway: AR can activate MAPK signaling, leading to cell growth.

4. Wnt/β-catenin pathway: AR may cross-talk with Wnt signaling to influence cell differentiation.

In AIS, loss of AR function leads to impaired development, but in cancer, AR mutations can lead to constitutive activation or altered ligand specificity.

Data from ClinVar and COSMIC databases (accessed 2023).

In AIS, the primary defect is in AR signaling, but downstream networks are also affected. Key nodes include:

• • AR co-regulators: NCOA1, NCOA2, NCOR1, NCOR2.
• • Transcription factors: FOXA1, GATA2, and ERG.
• • Growth factor receptors: EGFR, IGF1R.
• • Cell cycle regulators: CDK1, CCND1.
• • Apoptosis regulators: BCL2, BAX.

These networks are often deregulated in prostate cancer, where AR mutations can lead to constitutive activity.

Organoids derived from AIS patients can be generated from induced pluripotent stem cells (iPSCs) or primary tissue, providing a more physiologically relevant model for studying AR mutations.

Animal models for AIS include:

• • Tfm (testicular feminization) mouse: Spontaneous AR mutation (R871G) leading to complete androgen insensitivity.
• • AR knockout mouse: Global or conditional AR knockout models.
• • Patient-derived xenografts (PDX) of prostate cancer with AR mutations.
• • Genetically engineered mouse models (GEMM) with specific AR mutations.

These models are useful for studying the physiological effects of AR loss or mutation.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific AR mutations. For example:

• • AR knockout cell lines: Generated by introducing frameshift mutations in AR, resulting in complete loss of protein expression.
• • AR point-mutation knock-in lines: For example, introducing the T877A mutation into a wild-type AR background to study its oncogenic effects.
• • AR splice variant models: Overexpression or knock-in of AR-V7 to study its role in castration-resistant prostate cancer.

These models are commercially available and sequence-verified, providing a reliable tool for drug discovery and functional genomics. They allow researchers to study the impact of specific mutations in a controlled genetic background, accelerating research.

Gene-edited cell lines are essential for functional genomics studies. For example:

• • AR knockout cell lines can be used to identify AR-dependent genes and pathways.
• • Knock-in of specific AR mutations can reveal their effect on transcriptional activity.
• • CRISPR screens using AR knockout cells can identify synthetic lethal partners.

These approaches help validate the role of AR in disease and identify potential therapeutic targets.

Isogenic pairs (wild-type vs. mutant) are powerful tools for drug screening. For example:

• • Screening compounds against AR mutant cell lines can identify drugs that specifically target mutant AR.
• • Resistance to anti-androgens (e.g., enzalutamide) can be modeled by exposing AR mutant cells to the drug and selecting resistant clones.
• • Gene-edited cells can be used to test combination therapies.

This accelerates the development of precision medicine approaches.

CRISPR synthetic lethality screens can identify biomarkers for patient stratification. For example:

• • In AR-negative prostate cancer cells, knocking out AR may reveal dependencies on other pathways.
• • Gene-edited cells can be used to identify gene expression signatures associated with specific AR mutations.
• • These biomarkers can guide clinical trial design and patient selection.